We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vale (VALE) Beats on Q2 Earnings, Misses Revenue Estimates
Read MoreHide Full Article
VALE S.A. (VALE - Free Report) reported second-quarter 2018 earnings of 40 cents per share, which surged around 150% year over year. The bottom line also surpassed the Zacks Consensus Estimate of 14 cents, by a wide margin of around 186%.
Net operating revenues increased 19% year over year to $8,616 million in the quarter, primarily on the back of higher Base Metal’s sales prices, and increased sales volume of Ferrous Minerals and Base Metals. However, the top line missed the Zacks Consensus Estimate of $8,747 million by 1.5%.
Of the total net operating revenues, sales of ferrous minerals accounted for 73.4%, coal contributed 4.1%, base metals comprised 21.7%, and the remaining 0.8% was sourced miscellaneously.
Geographically, 10.6% of revenues were generated from South America, 58.5% from Asia, 6.7% from North America, 18% from Europe, 2.9% from the Middle East, and 3.3% from Rest of the World.
Costs & Margins
Cost of goods sold was $5,377 million in the reported quarter, up 5.4% year over year. This upswing resulted from elevated oil costs, higher freight rates, impact of the truck drivers’ strike and higher maintenance costs.
Gross margin was 37.6%, up 810 basis points year over year. Selling, general and administrative expenditure dropped 7.6% to $122 million, while research and development expenses flared up 15% to $92 million, both on a year-over-year basis.
Balance Sheet and Cash Flow
Vale exited the second quarter with cash and cash equivalents of $6,369 million, higher than the $5,720 million recorded in the year-ago quarter. During the quarter, Vale’s loans and borrowings came in at $16,084 million, down from $25,789 million recorded in the year-ago quarter.
In the June-end quarter, the company generated $3,544 million cash from operating activities, as against $3,443 million recorded in the year-ago quarter. Notably, the company's loans and financing repayment totaled $2,599 million in the quarter, up from $1,852 recorded in the prior-year quarter.
Vale announced a share-buyback program of $1 billion to be executed within a year. Per Vale’s new dividend policy, the company has announced to pay $2.05 billion to be paid in September 2018.
Capital spending summed $705 million in the second quarter, as against $890 million recorded in the previous-year quarter.
Share Price Performance
Shares of the company have outperformed the industry, over the past year. The stock has gained around 46% compared with 45% growth recorded by the industry during the same time period.
BHP Billiton has a long-term earnings growth rate of 5.3%. Its shares have rallied around 22%, over the past year.
Celanese has a long-term earnings growth rate of 9.3%. The company’s shares have gained around 23% in the past year.
KMG Chemicals has a long-term earnings growth rate of 28.5%. The company’s shares have surged around 45% in a year’s time.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits. Click here to see the 5 stocks >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Vale (VALE) Beats on Q2 Earnings, Misses Revenue Estimates
VALE S.A. (VALE - Free Report) reported second-quarter 2018 earnings of 40 cents per share, which surged around 150% year over year. The bottom line also surpassed the Zacks Consensus Estimate of 14 cents, by a wide margin of around 186%.
Net operating revenues increased 19% year over year to $8,616 million in the quarter, primarily on the back of higher Base Metal’s sales prices, and increased sales volume of Ferrous Minerals and Base Metals. However, the top line missed the Zacks Consensus Estimate of $8,747 million by 1.5%.
Of the total net operating revenues, sales of ferrous minerals accounted for 73.4%, coal contributed 4.1%, base metals comprised 21.7%, and the remaining 0.8% was sourced miscellaneously.
VALE S.A. Price, Consensus and EPS Surprise
VALE S.A. Price, Consensus and EPS Surprise | VALE S.A. Quote
Geographically, 10.6% of revenues were generated from South America, 58.5% from Asia, 6.7% from North America, 18% from Europe, 2.9% from the Middle East, and 3.3% from Rest of the World.
Costs & Margins
Cost of goods sold was $5,377 million in the reported quarter, up 5.4% year over year. This upswing resulted from elevated oil costs, higher freight rates, impact of the truck drivers’ strike and higher maintenance costs.
Gross margin was 37.6%, up 810 basis points year over year. Selling, general and administrative expenditure dropped 7.6% to $122 million, while research and development expenses flared up 15% to $92 million, both on a year-over-year basis.
Balance Sheet and Cash Flow
Vale exited the second quarter with cash and cash equivalents of $6,369 million, higher than the $5,720 million recorded in the year-ago quarter. During the quarter, Vale’s loans and borrowings came in at $16,084 million, down from $25,789 million recorded in the year-ago quarter.
In the June-end quarter, the company generated $3,544 million cash from operating activities, as against $3,443 million recorded in the year-ago quarter. Notably, the company's loans and financing repayment totaled $2,599 million in the quarter, up from $1,852 recorded in the prior-year quarter.
Vale announced a share-buyback program of $1 billion to be executed within a year. Per Vale’s new dividend policy, the company has announced to pay $2.05 billion to be paid in September 2018.
Capital spending summed $705 million in the second quarter, as against $890 million recorded in the previous-year quarter.
Share Price Performance
Shares of the company have outperformed the industry, over the past year. The stock has gained around 46% compared with 45% growth recorded by the industry during the same time period.
Zacks Rank & Key Picks
Vale currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same sector include BHP Billiton Limited (BHP - Free Report) , Celanese Corporation (CE - Free Report) and KMG Chemicals, Inc. . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BHP Billiton has a long-term earnings growth rate of 5.3%. Its shares have rallied around 22%, over the past year.
Celanese has a long-term earnings growth rate of 9.3%. The company’s shares have gained around 23% in the past year.
KMG Chemicals has a long-term earnings growth rate of 28.5%. The company’s shares have surged around 45% in a year’s time.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>